A case of pyoderma gangrenosum with ulcerative colitis treated with combined approach: Infliximab and surgery

Andrisani, Gianluca; Guidi, L.; Papa, Alfredo; Potenza, AE; Cervelli, Daniele; Armuzzi, Alessandro

doi:10.1016/j.crohns.2012.07.021

Cited by 18 publications

(12 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Andrisani et al . [ 28 ] confirmed effectiveness of infliximab (TNF-α inhibitor) for the treatment of PG of the left chest area in a patient with associated ulcerative colitis. Also Mooij et al .…”

Section: Discussionmentioning

confidence: 95%

Extensive phlegmon and pyoderma gangrenosum: diagnostic difficulties

Wcisło‐Dziadecka¹,

Bergler‐Czop²,

Brzeźińska-Wcisło³

et al. 2015

pdia

View full text Add to dashboard Cite

Pyoderma gangrenosum (PG) is a relatively rare neutrophilic dermatosis, characterized by progressive skin necrosis. It typically has a chronic course, of unknown etiology. Pyoderma gangrenosum diagnosis can be difficult because both histopathological examination and results of additional laboratory tests are not specific and the clinical state is conclusive, as for other physicians it poses a number of diagnostic dilemmas. Therefore, this condition should be treated interdisciplinary. We present a case of a 40-year-old patient with a diagnosis of PG, which in the early stages of the disease was treated as an extensive phlegmon by physicians of other specialties and it presented a serious diagnostic as well as therapeutic problem.

show abstract

Section: Discussionmentioning

confidence: 95%

Extensive phlegmon and pyoderma gangrenosum: diagnostic difficulties

Wcisło‐Dziadecka¹,

Bergler‐Czop²,

Brzeźińska-Wcisło³

et al. 2015

pdia

View full text Add to dashboard Cite

show abstract

“…A total of 3212 unique citations were found. 1286 and 1704 citations were excluded by abstract and full‐text read, respectively, yielding 222 articles…”

Section: Resultsmentioning

confidence: 99%

Pyoderma gangrenosum and tumour necrosis factor alpha inhibitors: A semi‐systematic review

Abdallah

Fogh

Bech

2019

International Wound Journal

View full text Add to dashboard Cite

Pyoderma gangrenosum (PG) is a rare ulcerative skin disease that presents a therapeutic challenge. Tumour necrosis factor alpha (TNFα) inhibitors have been reported to successfully control PG. Our aim was to systematically evaluate and compare the clinical effectiveness of TNFα inhibitors in adults with PG. A literature search including databases such as PubMed, Embase, Scopus, and Web of Science was conducted, using search terms related to PG and TNFα inhibitors. Studies and case reports were included if patients were diagnosed with PG, over the age of 18 and administered TNFα inhibitor. A total of 3212 unique citations were identified resulting in 222 articles describing 356 patients being included in our study. The study we report found an 87% (95% CI: 83%‐90%) response rate and a 67% (95% CI: 62%‐72%) complete response rate to TNFα inhibitors. No statistically significant differences in the response rates (P = 0.6159) or complete response rates (P = 0.0773) to infliximab, adalimumab, and etanercept were found. In our study TNFα inhibitors demonstrated significant effectiveness with response and complete response rates supporting the use of TNFα inhibitors to treat PG in adults. Our study suggests that there is no significant difference in effectiveness among infliximab, adalimumab, and etanercept.

show abstract

“…PG, an immune‐mediated skin inflammation, commonly occurs in 1–2% of IBD patients, whereas up to 50% of PG patients have active IBD . Its pathogenesis is not completely clear, but TNF α seems to play a role in mediating skin damage, since anti‐TNF α antibodies have been successfully used for its treatment . Even less is known about pulmonary lesions (PLs) in IBD setting, as they are very uncommon .…”

Section: Discussionmentioning

confidence: 99%